Anorexia nervosa (AN) is associated with food restriction and significantly low body weight, but the neurobiology of food avoidance in AN is unknown. Animal research suggests that food avoidance can be triggered by conditioned fear that engages the anterior cingulate and nucleus accumbens. We hypothesized that the neural activation during food avoidance in AN could be modeled based on aversive goal value processing. Nineteen females with AN and thirty healthy controls matched for age underwent functional magnetic resonance brain imaging while conducting a food avoidance task. During active control free-bid and computer-generated forced-bid trials, participants bid money to avoid eating food items. Brain activation was parametrically modulated with the trial-by-trial placed bids. During free-bid trials, the AN group engaged the caudate nucleus, nucleus accumbens, ventral anterior cingulate, and inferior and medial orbitofrontal cortex more than the control group. High- versus low-bid trials in the AN group were associated with higher caudate nucleus response. Emotion dysregulation and intolerance of uncertainty scores were inversely associated with nucleus accumbens free-bid trial brain response in AN. This study supports the idea that food avoidance behavior in AN involves aversive goal value computation in the nucleus accumbens, caudate nucleus, anterior cingulate, and orbitofrontal cortex.
1 November 2022 in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
Objective: Anorexia nervosa (AN) is a severe psychiatric disorder marked by an intense fear of gaining weight and persistent body dissatisfaction, both during periods of underweight and after weight restoration. The endocannabinoid system may offer therapeutic benefits, particularly in reducing anxiety. This randomized controlled trial of cannabidiol (CBD) investigated safety, tolerability, pharmacokinetics, and symptomatic improvement in AN. Method: In a double‐blind design, women with AN or Atypical AN were randomized to receive CBD ( n = 16) or placebo ( n = 16) over 21 days. The dose was up‐titrated weekly from 1.25 mg/kg twice daily to a maximum of 6.25 mg/kg twice daily, while assessing CBD and metabolite levels, liver function, and severity of eating disorder, depression, and anxiety symptoms. Results: Age at baseline was similar between the CBD and placebo group (22.9 ± 2.8 years vs. 22.5 ± 3.5 years), as was body mass index (BMI, kg/m 2 , 20.1 ± 2.5 vs. 19.4 ± 1.8). CBD demonstrated the expected pharmacokinetics with limited and nonserious adverse events. Repeated measures MANCOVA indicated a small but significant group‐by‐time interaction for BMI increase in favor of CBD (F = 3.039, p = 0.046, partial η2 = 0.252). Effect sizes for improvements in shape concern and perception of lack of control over eating were also large (partial η2 > 0.14), favoring CBD but nonsignificant. Discussion: This study suggests that CBD is well tolerated in individuals with AN. Furthermore, indication of better weight recovery and improvement of eating disorder specific symptoms in the CBD group suggest treatment effects of CBD in AN. The study was, however, constrained by its small sample size and limited duration and requires replication in a larger sample. Trial Registration: ClinicalTrials.gov identifier NCT04878627
30 June 2026 in International Journal of Eating Disorders